Upregulated Annexin A1 promotes cellular invasion in triple-negative breast cancer

Okano,Maiko; Kumamoto,Kensuke; Saito,Motonobu; Onozawa,Hisashi; Saito,Katsuharu; Abe,Noriko; Ohtake,Tohru; Takenoshita,Seiichi

doi:10.3892/or.2015.3720

Upregulated Annexin A1 promotes cellular invasion in triple-negative breast cancer

Authors:
- Maiko Okano
- Kensuke Kumamoto
- Motonobu Saito
- Hisashi Onozawa
- Katsuharu Saito
- Noriko Abe
- Tohru Ohtake
- Seiichi Takenoshita
View Affiliations

Affiliations: Department of Organ Regulatory Surgery, Fukushima Medical University School of Medicine, Fukushima 960‑1295, Japan
Published online on: January 14, 2015 https://doi.org/10.3892/or.2015.3720
Pages: 1064-1070

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Annexin A1 (ANXA1) is a calcium-dependent phospholipid-linked protein, involved in anti-inflammatory effects, regulation of cellular differentiation, proliferation and apoptosis. While many studies have investigated the ANXA1 expression in various tumor types, the role of ANXA1 is not fully understood. Therefore, in the present study, we evaluated the ANXA1 expression in 211 breast cancer patients and compared the levels with clinicopathological factors. ANXA1 was positively expressed in 31 (14.7%) of the 211 cases in our cohort, and these positive cases were associated with triple-negative breast cancer (TNBC) (P=0.007) and venous invasion (P=0.028). The in vitro cell experiment found that the MDA-MB-231 cell line, which is a TNBC cell line, highly expressed ANXA1. Using this cell line, the functional role of ANXA1 in breast cancer was revealed and the knockdown of ANXA1 by specific siRNA demonstrated a significant reduction in cellular invasion. Further experiments indicated that ANXA1 was induced by hypoxia with hypoxia-inducible factor-1α induction. These results suggested that ANXA1, which enhanced breast cancer invasion and metastasis under hypoxia, were significantly associated with the worst patient outcome. This is particularly noted in TNBC, the group of breast cancer with the worst outcome for which new therapeutic implications are required.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Early Breast Cancer Trialists’ Collaborative Group. Davies C, Godwin J, et al: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 378:771–784. 2011. View Article : Google Scholar : PubMed/NCBI
3	Early Breast Cancer Trialists’ Collaborative Group. Peto R, Davies C, et al: Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 379:432–444. 2012. View Article : Google Scholar
4	Gianni L, Dafni U, Gelber RD, et al: Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 12:236–244. 2011. View Article : Google Scholar : PubMed/NCBI
5	Cortazar P, Zhang L, Untch M, et al: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 384:164–172. 2014. View Article : Google Scholar : PubMed/NCBI
6	Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
7	Turner NC and Reis-Filho JS: Tackling the diversity of triple-negative breast cancer. Clin Cancer Res. 19:6380–6388. 2013. View Article : Google Scholar : PubMed/NCBI
8	Cancer Genome Atlas Research Network. Kandoth C, Schultz N, et al: Integrated genomic characterization of endometrial carcinoma. Nature. 497:67–73. 2013. View Article : Google Scholar : PubMed/NCBI
9	Rescher U and Gerke V: Annexins - unique membrane binding proteins with diverse functions. J Cell Sci. 117:2631–2639. 2004. View Article : Google Scholar : PubMed/NCBI
10	Parente L and Solito E: Annexin 1: more than an anti-phospholipase protein. Inflamm Res. 53:125–132. 2004. View Article : Google Scholar : PubMed/NCBI
11	Lim LH and Pervaiz S: Annexin 1: the new face of an old molecule. FASEB J. 21:968–975. 2007. View Article : Google Scholar : PubMed/NCBI
12	Garcia Pedrero JM, Fernandez MP, Morgan RO, et al: Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status. Am J Pathol. 164:73–79. 2004. View Article : Google Scholar
13	Luo A, Kong J, Hu G, et al: Discovery of Ca2⁺-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray. Oncogene. 23:1291–1299. 2004. View Article : Google Scholar
14	Sinha P, Hütter G, Köttgen E, Dietel M, Schadendorf D and Lage H: Increased expression of annexin I and thioredoxin detected by two-dimensional gel electrophoresis of drug resistant human stomach cancer cells. J Biochem Biophys Methods. 37:105–116. 1998. View Article : Google Scholar : PubMed/NCBI
15	Duncan R, Carpenter B, Main LC, Telfer C and Murray GI: Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer. 98:426–433. 2008. View Article : Google Scholar
16	Sato Y, Kumamoto K, Saito K, et al: Up-regulated Annexin A1 expression in gastrointestinal cancer is associated with cancer invasion and lymph node metastasis. Exp Ther Med. 2:239–243. 2011.PubMed/NCBI
17	Bai XF, Ni XG, Zhao P, et al: Overexpression of annexin 1 in pancreatic cancer and its clinical significance. World J Gastroenterol. 10:1466–1470. 2004.PubMed/NCBI
18	Masaki T, Tokuda M, Ohnishi M, et al: Enhanced expression of the protein kinase substrate annexin in human hepatocellular carcinoma. Hepatology. 24:72–81. 1996.PubMed/NCBI
19	Kang JS, Calvo BF, Maygarden SJ, Caskey LS, Mohler JL and Ornstein DK: Dysregulation of annexin I protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Clin Cancer Res. 8:117–123. 2002.PubMed/NCBI
20	Pencil SD and Toth M: Elevated levels of annexin I protein in vitro and in vivo in rat and human mammary adenocarcinoma. Clin Exp Metastasis. 16:113–121. 1998. View Article : Google Scholar : PubMed/NCBI
21	Ahn SH, Sawada H, Ro JY and Nicolson GL: Differential expression of annexin I in human mammary ductal epithelial cells in normal and benign and malignant breast tissues. Clin Exp Metastasis. 15:151–156. 1997. View Article : Google Scholar : PubMed/NCBI
22	Wang LP, Bi J, Yao C, et al: Annexin A1 expression and its prognostic significance in human breast cancer. Neoplasma. 57:253–259. 2010. View Article : Google Scholar : PubMed/NCBI
23	Shen D, Chang HR, Chen Z, et al: Loss of annexin A1 expression in human breast cancer detected by multiple high-throughput analyses. Biochem Biophys Res Commun. 326:218–227. 2005. View Article : Google Scholar
24	Shen D, Nooraie F, Elshimali Y, et al: Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis. Hum Pathol. 37:1583–1591. 2006. View Article : Google Scholar : PubMed/NCBI
25	Cao Y, Li Y, Edelweiss M, et al: Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol. 16:530–534. 2008. View Article : Google Scholar : PubMed/NCBI
26	Bist P, Leow SC, Phua QH, et al: Annexin-1 interacts with NEMO and RIP1 to constitutively activate IKK complex and NF-κB: implication in breast cancer metastasis. Oncogene. 30:3174–3185. 2011. View Article : Google Scholar : PubMed/NCBI
27	de Graauw M, van Miltenburg MH, Schmidt MK, et al: Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. Proc Natl Acad Sci USA. 107:6340–6345. 2010. View Article : Google Scholar : PubMed/NCBI
28	Saito M, Matsuzaki M, Sakuma T, et al: Clinicopathological study of non-palpable familial breast cancer detected by screening mammography and diagnosed as DCIS. Breast Cancer. 21:140–145. 2014. View Article : Google Scholar
29	Saito M, Shiraishi K, Matsumoto K, et al: A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma. Clin Cancer Res. 20:4784–4793. 2014. View Article : Google Scholar : PubMed/NCBI
30	Mastro AM and Vogler EA: A three-dimensional osteogenic tissue model for the study of metastatic tumor cell interactions with bone. Cancer Res. 69:4097–4100. 2009. View Article : Google Scholar : PubMed/NCBI
31	Nicolson GL, Nawa A, Toh Y, Taniguchi S, Nishimori K and Moustafa A: Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer cell invasion, proliferation and nuclear regulation. Clin Exp Metastasis. 20:19–24. 2003. View Article : Google Scholar : PubMed/NCBI
32	Chen WT, Lee CC, Goldstein L, et al: Membrane proteases as potential diagnostic and therapeutic targets for breast malignancy. Breast Cancer Res Treat. 31:217–226. 1994. View Article : Google Scholar : PubMed/NCBI
33	Wang Y, Serfass L, Roy MO, Wong J, Bonneau AM and Georges E: Annexin-I expression modulates drug resistance in tumor cells. Biochem Biophys Res Commun. 314:565–570. 2004. View Article : Google Scholar : PubMed/NCBI
34	Chuthapisith S, Bean BE, Cowley G, et al: Annexins in human breast cancer: Possible predictors of pathological response to neoadjuvant chemotherapy. Eur J Cancer. 45:1274–1281. 2009. View Article : Google Scholar : PubMed/NCBI
35	Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
36	Gardner LB, Li Q, Park MS, Flanagan WM, Semenza GL and Dang CV: Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem. 276:7919–7926. 2001. View Article : Google Scholar
37	Giatromanolaki A, Koukourakis MI, Sivridis E, et al: Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer. 85:881–890. 2001. View Article : Google Scholar : PubMed/NCBI
38	Liu L, Ning X, Sun L, et al: Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci. 99:121–128. 2008.
39	Schindl M, Schoppmann SF, Samonigg H, et al: Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res. 8:1831–1837. 2002.PubMed/NCBI
40	Welsh SJ, Bellamy WT, Briehl MM and Powis G: The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res. 62:5089–5095. 2002.PubMed/NCBI
41	Keith B, Johnson RS and Simon MC: HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 12:9–22. 2012.